Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
The revolutionary new nano coating is easy to apply and rejects liquid-based contagions like COVID-19/SARS-CoV-2 and variants, influenzas, and rhinoviruses and is available via ready-to-use sprays or pre-treated air filters
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Subscribe To Our Newsletter & Stay Updated
